Business Context and Reporting Period
This Form 8-K filing by InMed Pharmaceuticals Inc. (INM) reports on the Annual and Special General Meeting of Shareholders held on November 20, 2020. The company is incorporated in British Columbia and trades on The Nasdaq Stock Market.
Key Financial Metrics
This filing is a current report regarding corporate governance and shareholder votes. It does not contain financial statements, revenue, profit, cash flow, margin, debt, or liquidity data.
Material Changes
The filing details the outcomes of four shareholder proposals, all of which were approved:
- Election of Directors: Shareholders elected five directors (Eric A. Adams, Adam Cutler, William J. Garner, Andrew Hull, and Catherine Sazdanoff) to serve until the 2021 Annual General Meeting. Support ranged from 90.84% to 93.01%.
- Appointment of Auditor: KPMG LLP was appointed as the independent registered public accounting firm with 97.50% support.
- Stock Option Plan Amendment: Approved an amendment to update the definition of "Blackout Period" and extend the exercise period post-blackout. This received 82.03% support.
- Articles Amendment: Approved an amendment to Section 11.3 of the Articles to increase the quorum requirement for shareholder meetings to two persons holding or representing at least 33-1/3% of outstanding common shares. This received 91.75% support.
Guidance, Outlook, and Risks
The filing text does not provide management commentary, financial guidance, outlook, or specific risk factors beyond the standard disclosure of the voting results.
Investor Verification Checklist
- Verify the new quorum requirements for future shareholder meetings (33-1/3% of outstanding shares).
- Confirm the updated terms of the Stock Option Plan regarding Blackout Periods.
- Review the tenure of the newly elected board members (until the 2021 AGM).
- Note the significant number of broker non-votes (1,672,478) recorded for the director elections and stock option plan amendment.